Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib

Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib

Objectives: The purpose of this study was to assess osimertinib-associated cardiac adverse events (AEs) in a real-world setting, using a retrospective single-center cohort study in Japan. Background: Cases of osimertinib-associated cardiac AEs have been reported but remain poorly understood. Methods...

Full description

Bibliographic Details
Main Authors: Kei Kunimasa, MD, PhD, Risa Kamada, MD, Toru Oka, MD, PhD, Makiko Oboshi, MD, PhD, Madoka Kimura, MD, Takako Inoue, MD, Motohiro Tamiya, MD, Tatsuya Nishikawa, MD, PhD, Taku Yasui, MD, PhD, Wataru Shioyama, MD, PhD, Kazumi Nishino, MD, PhD, Fumio Imamura, MD, PhD, Toru Kumagai, MD, PhD, Masashi Fujita, MD, PhD
Format: Article
Language:English
Published: Elsevier 2020-03-01
Series:JACC. CardioOncology
Subjects:
cardiac adverse events
cardiac dysfunction
EGFR mutations
myocardial biopsy
non–small cell lung cancer
osimertinib
Online Access:http://www.sciencedirect.com/science/article/pii/S2666087320300107

Internet

http://www.sciencedirect.com/science/article/pii/S2666087320300107

Similar Items